Copper-binding tripeptide / cosmetic active / investigational regenerative

GHK-Cu

CAS: 49557-75-7 MW: ~402.9 g/mol Formula: C₁₄H₂₄N₆O₄

1. Identity

Field	Value
Chemical name	Glycyl-L-histidyl-L-lysine : copper(II), 1:1 complex
INN / WHO drug name	None assigned
INCI name	Copper Tripeptide-1
CAS (free tripeptide GHK)	72957-37-0
CAS (1:1 Cu²⁺ complex GHK-Cu)	49557-75-7
Molecular formula (free GHK)	C₁₄H₂₄N₆O₄
MW (free GHK)	340.38 g/mol
MW (GHK-Cu 1:1)	~402.9 g/mol (varies with counter-ion / hydration)
Class	Small endogenous tripeptide; Cu(II)-chelator; cosmetic active; investigational regenerative agent
Historical brands	Iamin Gel®, Iamin Hydrating Gel® (ProCyte; FDA 510(k) Class I wound dressing, 1996; discontinued post-PhotoMedex acquisition); SkinMedica TNS Recovery Complex (legacy); Neutrogena Visibly Firm (legacy)
Current cosmetic SKUs	NIOD CAIS (Deciem); The Ordinary “Buffet + Copper Peptides 1%”; Skin Biology Inc product line (Pickart’s company 🔴); NEEL Gel (Yuvan Research 2023 ⚠️); innumerable cosmetic SKUs under INCI “Copper Tripeptide-1”
Identifiers	PubChem CID 73587187 (GHK-Cu complex); CID 92805 (free GHK); DrugBank DB12815

Source labels for Section 1: [Academic secondary — PubChem; DrugBank DB12815]; [Regulatory — EU CosIng; FDA cosmetic ingredient inventory; FDA 510(k) Feb 1996].

2. History and Development

GHK was isolated from the human plasma albumin fraction in 1973 by Loren Pickart at the University of California–San Francisco; the original observation was that plasma from young donors restored protein-synthetic activity in liver cells from older donors, and the active factor was identified as the tripeptide Gly-His-Lys [Peer-reviewed historical — Pickart & Thaler 1973 Nature New Biol 243:85–87]. Pickart subsequently characterised the high-affinity Cu²⁺ binding (log K ≈ 16.4, marginally exceeding albumin’s copper-transport site) at UCSF and the University of Washington 🔴 [single-group dependency throughout the foundational mechanistic literature].

Plasma GHK concentration is widely cited as declining from approximately 200 ng/mL at age 20 to approximately 80 ng/mL at age 60 — a figure traceable to Pickart’s own work and repeated through subsequent secondary reviews 🔴 [Peer-reviewed — Pickart & Margolina 2018 Int J Mol Sci 19:1987, PMID 29986520; ⚠️ author affiliation Skin Biology Inc].

Commercial development began in the late 1980s under ProCyte Corporation (Kirkland, WA), which licensed the technology and pursued the diabetic foot ulcer indication in partnership with Schering-Plough from 1989. Phase III trials of “Iamin” (peptide-copper hydrogel) failed to outperform placebo in a 511-patient pivotal trial in October 1994, ending the drug-approval pathway [Industry-trade contemporaneous — Seattle Times archive 1996; Pink Sheet / Scrip industry reports 1992–1997]. ProCyte then re-submitted the same compound as a Class I medical device (510(k) pathway), which was cleared by FDA on 7 February 1996 for use as a wound dressing in diabetic, venous and mixed-etiology leg ulcers, pressure sores, first- and second-degree burns, donor sites, and surgical wounds — without permission to claim “healing” [Regulatory — FDA 510(k) clearance Feb 1996; ProCyte announcement; FDA Class 2 Device Recall record id 135054 on later Iamin lots]. A separate later 510(k) (K964468, “IAMIN WET DRESSING (COPPER-SALINE)”) covered a saline-based variant. ProCyte was acquired by PhotoMedex in 2005, and the Iamin line was discontinued. GHK-Cu then migrated to ubiquitous cosmetic use under INCI Copper Tripeptide-1.

In 2010, the Broad Institute’s Connectivity Map dataset placed GHK among compounds that broadly shift gene-expression signatures, which Pickart’s group subsequently interpreted as modulating “more than 4,000 human genes” — a claim repeated throughout secondary literature 🔴 [Peer-reviewed — Pickart, Vasquez-Soltero & Margolina 2014 BioMed Res Int 151479; Pickart & Margolina 2018]. A 2023 EurekAlert press release from Yuvan Research Inc described a 21-volunteer IRB-approved open trial of a proprietary GHK-Cu gel (“NEEL”) reporting a 28% mean and 51% top-quartile increase in dermal collagen density at 3 months ⚠️ [Press release — not peer-reviewed; industry-sponsored].

Community-side history (see Section 7B for full treatment): The molecule has the longest community lineage of any peptide currently discussed in the optimization space. The topical-cosmetic audience has a 30-year head start through the 1990s ProCyte → mid-2000s SkinMedica/Neutrogena licensing → 2014 Deciem NIOD CAIS launch. The injectable grey-market phase emerged roughly 2018–2022, driven by Ben Greenfield and Jay Campbell podcasts and the Aseir Custom / Auxano product launch. The 2023–2026 phase is a TikTok-driven “skin longevity” revival on the topical side, paired with a contraction of the injectable channel after the April 2026 FDA 503A nomination withdrawals.

3. Mechanism of Action

Demonstrated in humans (status: DEMONSTRATED — topical only)

Topical fibroblast collagen / elastin / glycosaminoglycan upregulation — confirmed in human skin biopsies from controlled cosmetic trials at 0.1–2% topical concentrations [Peer-reviewed human study — Abdulghani et al. 1998 Dis Manag Clin Outcomes 1:136–141, n=20 ⚠️ small pilot]; [Finkley, Appa & Bhandarkar 2005 book chapter, Cosmeceuticals and Active Cosmetics, Marcel Dekker, n=67 women, 12 weeks ⚠️ Neutrogena-funded; non-journal venue].
High-affinity Cu(II) chelation with stable copper transfer into cells via the CTR1 importer after extracellular reduction to Cu(I) [Peer-reviewed mechanistic — Bal et al. 2021 Inorg Chem, PMC8653159].
MMP-1 / MMP-2 / TIMP-1 / TIMP-2 modulation in cultured human dermal fibroblasts and confirmed in skin biopsy mRNA quantification in a 40-subject 8-week split-face trial [Peer-reviewed human study — Badenhorst et al. 2016 J Aging Sci 4:166 ⚠️ industry-funded].

Proposed / preclinical only (status: PROPOSED)

SIRT1 binding and STAT3 modulation — molecular docking (−8.75 kcal/mol; residues GLU-230, ASN-226) plus DSS-colitis mouse model: GHK-Cu upregulates SIRT1, suppresses p-STAT3, restores ZO-1 and Occludin tight-junction proteins, reduces TNF-α / IL-6 / IL-1β [Peer-reviewed preclinical — Mao et al. 2025 Front Pharmacol 16:1551843, PMID 40672369; Jining Medical University, China]. Significance: first major non-Pickart-lab mechanistic linkage to a longevity-relevant target. Murine only.
Connectivity Map gene-signature pattern matching — the “4,000+ gene modulation” claim is signature-similarity pattern matching across the Broad’s CMap dataset, not direct measurement of GHK-Cu effects on those genes [Peer-reviewed — Pickart et al. 2014 🔴]. The claim is mechanistic plausibility, not human pharmacodynamics.
VEGF up-regulation, decorin synthesis, angiogenesis — preclinical [Peer-reviewed preclinical — Pickart 2015 BioMed Res Int PMID 26236730 🔴; multiple cosmetic-research groups].
Replicative-vitality restoration in irradiated fibroblasts [Peer-reviewed preclinical — McCormack & Pickart 2001 🔴].
Caspase-3 reduction (~42.7%) and Bcl-2/Bax pro-survival shift in dermal-papilla cells [Peer-reviewed preclinical — Pyo et al. 2007 Biofactors].

What is NOT mechanistically demonstrated in humans

Systemic gene-expression resetting after subcutaneous injection — no human pharmacokinetic, pharmacodynamic or biomarker dataset exists.
Horvath / GrimAge / DunedinPACE epigenetic-clock reversal in humans — the “epigenetic age reversal” framing is a Connectivity Map gene-signature similarity argument, not a methylation-clock measurement ⚠️🔴.
COPD reversal, post-COVID lung repair, lung stem-cell activation — these claims (see Section 7B) trace to Pickart secondary reviews and a single HealthUnlocked forum thread; no human trial exists.

4. Regulatory Status

4.1 Drug-regulatory status

Jurisdiction	Status
FDA (US) — drug	No NDA, no IND on file for any drug indication. Iamin Phase III diabetic foot ulcer trial (n=511, 1994) failed to outperform placebo.
FDA (US) — device	510(k) Class I wound dressing, cleared 7 February 1996 (Iamin Hydrogel, ProCyte). Cleared for diabetic ulcers, venous/mixed-etiology leg ulcers, pressure sores, first- and second-degree burns, donor sites, surgical incisions, skin abrasions. No claim of “wound healing” permitted. Product discontinued post-2005 PhotoMedex acquisition. Variant K964468 (“IAMIN WET DRESSING (COPPER-SALINE)”) in 510(k) browser. FDA Class 2 device recall record id 135054 on later Iamin lots reflects manufacturing/quality action, not a clinical-safety signal.
FDA — cosmetic	INCI “Copper Tripeptide-1” — self-regulated cosmetic active. No FDA pre-approval. No regulatory-significant MedWatch signal as of 2026-05-13.
FDA — 503A compounding (verified against FDA media/94155 dated 22 April 2026)	GHK-Cu (non-injectable) — removed from Category 1 “because the nominations were withdrawn by the nominators.” GHK-Cu (injectable) — removed from Category 2 “because the nominations were withdrawn by the nominators.” Neither sits on the 503A bulks list as of 22 April 2026. PCAC consultation scheduled before the end of February 2027. This is the February 2027 PCAC subset (alongside Cathelicidin LL-37, Dihexa acetate, PEG-MGF, Melanotan II) — separate from the July 2026 subset (BPC-157, KPV, MOTs-C, TB-500, Emideltide/DSIP, Epitalon, Semax; written-comment deadline 9 July 2026). PCAC currently lists only four seated members; replacements pending.
FDA — 503B outsourcing	No movement onto a 503B bulks list signalled.
Practical compounding consequence (US)	Not legally compoundable under 503A in any route as of 22 April 2026, pending the February 2027 PCAC consultation. Removal from Category 2 does not authorise compounding. Formal rulemaking can take >12 months after PCAC.
EMA / EU	No marketing authorisation. INCI “Copper Tripeptide-1” permitted under Cosmetic Regulation (EC) No 1223/2009 with no Annex restriction.
MHRA (UK)	Same status as EU; cosmetic-only.
PMDA (Japan)	No approved drug product. Permitted as quasi-drug / cosmetic ingredient.
NMPA (China)	Permitted as cosmetic ingredient under IECIC inventory; no drug approval.
MFDS (South Korea)	Permitted as cosmetic ingredient.
TGA (Australia)	No ARTG drug entry; cosmetic-only.
Health Canada	Cosmetic-only; no DIN-issued drug product.
Russia GRLS	No registered medicinal product.
WHO Essential Medicines List	Not listed.

4.2 Anti-doping status

Field	Value
WADA Prohibited List status (2026)	Not named in S0, S1, S2, S2.2, S2.3, S4, S6, M1, M2, M3, or the 2026 Monitoring Program. The 2026 List and Monitoring Program came into force on 1 January 2026 [Regulatory — WADA, approved by ExCo 11 September 2025]. The 2026 modifications added clarifying examples to S2 (“Peptide hormones, growth factors, related substances and mimetics”) but did not add GHK-Cu by name.
Default categorisation rule for injectable use	S0 (Non-Approved Substances). GHK-Cu has no marketing authorisation as a pharmaceutical agent in any major regulator; injectable, intramuscular or other systemic administration falls within the S0 catch-all: “Any pharmacological substance which is not addressed by any of the subsequent sections … with no current approval by any governmental regulatory health authority for human therapeutic use.”
Alternative S2-by-function argument	The VEGF / growth-factor-modulating preclinical mechanism makes an S2 (“growth factors and growth factor modulators … and other substances with similar chemical structure or similar biological effect”) argument plausible, but it is not regulatorily anchored. Athletes facing an adverse analytical finding cannot rely on the absence of a named listing.
In-competition / out-of-competition	Both — S0 is prohibited at all times.
TUE eligibility	Not available. S0 substances have no approved therapeutic indication anywhere, so a TUE cannot be issued (a TUE must reference an approved drug for a documented medical condition).
Topical cosmetic use	Topical cosmetic use of GHK-Cu is not, in itself, an anti-doping concern. No reported cases of cosmetic-vehicle topical GHK-Cu causing an adverse analytical finding.
NCAA banned-drug-class status	Not specifically named on the NCAA banned-drug class list, but the NCAA prohibits “any substance that is pharmacologically related to a banned class” — a copper-peptide growth-factor-modulator would fall within the same defensive logic as WADA S0/S2-by-function.
DoD / OPSS status	Not on the DoD Prohibited Dietary Supplement Ingredients list as of the last public update; OPSS guidance is silent on GHK-Cu. Compare: BPC-157, TB-500 are explicitly DoD-prohibited.
Global DRO check date	Not specifically cross-checked against globaldro.com at this review (flagged for next refresh). Functionally, Global DRO would direct any athlete query to default anti-doping rules for an unapproved substance — i.e. prohibited by status.
Detection window	No published analytical-chemistry detection window for GHK-Cu in WADA-accredited laboratory routine LC-HRMS methods. The Tian 2023 anti-doping LC-HRMS work focused on BPC-157, not GHK-Cu. The free tripeptide GHK is endogenous in plasma; an exogenous-administration test would require either copper-stable-isotope tracing or a labelled synthetic analogue. Functionally undetectable by routine WADA assays at present. This is a feature the injectable community has not articulated explicitly — see Section 7B / Gap Analysis.
Notable sanctions / precedents	None for GHK-Cu specifically. Comparable copper-tripeptide / cosmetic-active sanctions: none reported.

4.3 Last regulatory review

Last regulatory review: 2026-05-13 — verified against FDA media/94155 (22 April 2026), WADA 2026 Prohibited List (effective 1 January 2026), and FDA 503A bulks list status. Next mandatory recheck triggers: any PCAC announcement before February 2027; WADA 2027 List preview (typically published October 2026); any NDA/IND filing.

5. Formulations and Routes

Route	Formulation	Concentration range in published studies	Status
Topical cream / serum / gel (cosmetic)	Aqueous gel; hydrogel; oil-in-water emulsion; lipid-nanocarrier serum; lecithin liposome	0.05% – 4% (most cosmetic SKUs 0.1–1%)	Approved cosmetic ingredient multi-jurisdiction; INCI Copper Tripeptide-1
Topical hydrogel (medical device)	Iamin Hydrogel	0.3% Cu-peptide complex	Historical: FDA-cleared Class I device 1996; product no longer marketed
Subcutaneous / intramuscular injection	Compounded sterile solution, typically 1–2 mg/mL in bacteriostatic saline	Community-reported 1–3 mg/day; 0.5 µg/kg in early rat work; no human dose-finding RCT exists	Investigational only. Not compoundable under 503A as of 22 April 2026.
Intranasal	15 mg/kg/day in murine cognition models	—	Preclinical only
Oral / liposomal / micellar / microemulsion / microneedle patch	Various emerging delivery systems addressing GHK-Cu hydrophilicity and poor stratum-corneum penetration	—	Investigational; multiple 2023–2025 preclinical proof-of-concept publications

Pharmacokinetic constraint repeatedly noted across recent reviews: standard topical aqueous formulations produce “almost no peptide or copper permeating through intact human skin” without specialised delivery systems (liposomes, microemulsions, microneedles) [Peer-reviewed — Mortazavi, Vadoud & Moghimi 2025 Bioimpacts 15:30071; Medsci tripeptide review 2024 PMC12595317]. This finding undercuts the bulk of low-cost cosmetic SKUs — a point the cosmetic-chemist community (Lab Muffin) has surfaced episodically but the broader skincare audience tends to ignore.

Community-side formulation practices (see Section 7B): Topical converged on 1–2% (occasionally 5%) once or twice daily, layered away from vitamin C, retinoids and acids. Injectable converged on 1–2 mg/day sub-Q with 30-on/30-off or 8-on/4-off cycling. Reconstitution stability: 28-day fridge stability for sub-Q reconstituted (Disclosed Labs); 6-month limit for two-part topicals (NIOD CAIS).

6. Preclinical Evidence

Fibroblast collagen / elastin / decorin synthesis: Stimulated at 1–10 nM in cultured human dermal fibroblasts [Peer-reviewed preclinical — Maquart et al. 1988–1993 series; Simeon, Wegrowski, Bontemps & Maquart 2000 J Invest Dermatol 115:962].
Aged-animal wound healing: Improved collagen / elastin biosynthesis and wound closure in aged rats [Peer-reviewed preclinical — Hinek et al. 1994 Mech Ageing Dev 77:211].
Irradiated-fibroblast restoration: Replicative vitality restored at nanomolar GHK-Cu [Peer-reviewed preclinical — McCormack & Pickart 2001 🔴].
Dermal-papilla / hair-follicle protection: Caspase-3 reduction ~42.7%, Bcl-2/Bax shift toward survival [Peer-reviewed preclinical — Pyo et al. 2007 Biofactors].
Ulcerative colitis (DSS-induced mouse model): GHK-Cu reduced weight loss, disease activity index, colonic edema/shortening; suppressed TNF-α, IL-6, IL-1β; upregulated SIRT1 and tight-junction proteins; molecular docking placed GHK in the SIRT1 binding pocket [Peer-reviewed preclinical — Mao et al. 2025 Front Pharmacol 16:1551843]. First independent mechanistic SIRT1 linkage in the literature; murine model only.
Dimeric GHK-Cu / smart-hydrogel wound dressings: Multiple 2024–2025 papers describe dimeric GHK constructs and stimulus-responsive hydrogel delivery systems with antibacterial and neovascularisation endpoints in rodent models [Peer-reviewed preclinical — multiple groups].
Topical-permeation problem confirmed: Mortazavi 2025 review explicitly catalogues the high-hydrophilicity / poor stratum-corneum penetration constraint and concludes specialised carriers are required for any meaningful dermal delivery [Peer-reviewed — Mortazavi 2025].
Epigenetic / methylation-clock human data: Absent as of 2026-05-13. The “epigenetic age reversal” narrative is supported by Connectivity Map gene-expression signature pattern matching, not by Horvath-style methylation-clock evidence. This distinction is widely flattened in community communications.

7. Clinical Evidence

Cochrane and systematic-review landscape

No Cochrane Systematic Review identified on GHK-Cu, copper tripeptide, or glycyl-histidyl-lysine for wound healing, skin aging, or hair growth as of 2026-05-13. The 2024 International Working Group on the Diabetic Foot (IWGDF) guideline does not recommend GHK-Cu (or related copper-peptide preparations) as adjunctive therapy in diabetic foot ulcers, on the basis of low-certainty evidence and the absence of robust RCTs [Regulatory / society guideline — IWGDF 2024]. A 2024 meta-analysis cited in tertiary aggregators (J Drugs Dermatol, 5 RCTs, n=289, SMD −0.68 for fine lines, 95% CI −1.02 to −0.34) appears in secondary literature; the underlying primary publication could not be independently verified at this review and remains flagged for verification ⚠️.

Pivotal randomised trials (chronological)

Year	First author	Design	n	Indication	Result	Funding	Flag
1994	Mulder GD (ProCyte Phase II)	RCT, 0.4% GHK-Cu vs placebo	31	Diabetic ulcers	GHK-Cu wound closure rate ~3× placebo; faster reepithelialisation	ProCyte	⚠️ industry
1994	ProCyte unpublished Phase III	RCT	511	Diabetic foot ulcers	Did NOT outperform placebo; ended drug-approval pathway	ProCyte	⚠️ negative pivotal
1998	Abdulghani et al.	Open comparator: GHK-Cu vs vitamin C vs tretinoin	20	Photoaged skin (ultrastructure)	GHK-Cu increased collagen in ~70% of volunteers	Academic	small pilot
2002	Leyden et al.	Vehicle-controlled, twice-daily eye cream	41	Periorbital photoaging	Improvements in fine lines, density, thickness vs vehicle	Industry	⚠️
2005	Finkley, Appa & Bhandarkar	RCT, 12 wk, 2× daily facial	67	Photoaging	Appearance, thickness, wrinkle improvements vs placebo	Neutrogena	⚠️ non-journal venue
2006	Miller et al.	Split-face RCT post-CO₂ laser resurfacing	small	Post-procedure erythema/healing	Accelerated reepithelialisation; reduced erythema	Industry	⚠️
2016	Lee WJ et al.	RCT GHK + 5-ALA scalp, 6 mo	small (~30)	Androgenetic alopecia	Significant hair-count increase vs placebo; no adverse events	Academic (Korea)	Peer-reviewed Ann Dermatol PMID 27489425
2016	Badenhorst et al.	RCT lipid-nano serum vs Matrixyl 3000 vs vehicle	40	Photoaging	MMP/TIMP/collagen modulation; 31.6% wrinkle-volume reduction	Industry	⚠️
2022	Dermatologic Therapy report (via aggregator)	RCT 1% GHK-Cu cream, 12 wk	71	Facial photoaging	Wrinkle reduction ~55.7%	Industry	⚠️ primary verification pending
2023	Yuvan Research (NEEL Gel)	IRB open trial, 3 mo	21	Skin collagen density	Mean +28%, top quartile +51% by dermal ultrasound	Yuvan Research Inc	⚠️ press release; not peer-reviewed
2024	Multiple post-laser-resurfacing studies (via aggregator)	RCT 0.05% gel	varied	Post-procedure recovery	~25% faster reepithelialisation; IL-1β / TNF-α reductions	Mixed	⚠️ verification pending
2025	Kuceki, Wambier et al.	Triple-active microneedling (GHK-Cu + minoxidil + dutasteride)	small	Androgenetic alopecia	26.5% regrowth; cannot isolate GHK-Cu contribution	Academic	confounded design
2025	Japanese 0.02% peptide lotion (via aggregator)	RCT, 16 wk	unspecified	Hair density	+7% hair count vs baseline; “mild and adjunctive” vs minoxidil	Industry	⚠️ verification pending

Active trial registry status

NCT05239615 — topical GHK-Cu for photoaging, Phase II, completed 2024, no results posted.
NCT04892136 — hair growth, Phase I/II, terminated 2023.
NCT02898454 — androgenetic alopecia, completed 2019 (preliminary positive signal).
“Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal)” — 0.1% w/w gel daily for 14 days vs standard non-adherent dressing; 12-week POSAS scar endpoint; NCT identifier not confirmed at this review.

Observational and registry data

No large prospective cosmetovigilance registry. FDA recall record for Iamin Moist Dressing / Hydrating Gel (id 135054) reflects manufacturing/quality-related action, not a clinical-safety signal.

7.5 Disputed Claims

Two substantive disputes are visible in the published literature and on the regulatory record. A third is methodological rather than substantive.

Dispute 1 — Diabetic foot ulcer efficacy: Mulder 1994 small-RCT positive vs ProCyte 1994 pivotal Phase III negative.

Position A (positive): Mulder GD et al. 1994 Wound Repair Regen 2:259 (PMID 17147644) reported wound closure of 89.2% vs −10.3% in larger (>100 mm²) ulcers, and ulcer infection 7% vs 34%, in a multicenter RCT of n≈30 plantar diabetic ulcers using Iamin gel vs vehicle. ⚠️ ProCyte employees among authors [Peer-reviewed human study].
Position B (negative): The unpublished ProCyte 511-patient pivotal Phase III in October 1994 failed to outperform placebo; this is documented through industry-trade press (Seattle Times, Pink Sheet, Scrip, BioWorld 1992–1997) and through the regulatory record — ProCyte abandoned the drug-approval pathway and pivoted to the 510(k) device-clearance route. ⚠️ ProCyte sponsored [Industry-trade contemporaneous].
Resolution: None. The small published RCT was positive; the larger unpublished pivotal was negative; FDA accepted the device clearance but not the drug claim. The IWGDF 2024 guideline does not recommend GHK-Cu for diabetic foot ulcers on grounds of low-certainty evidence. The negative pivotal is the higher-quality evidence, but it never reached peer-reviewed publication, which is itself a structural concern.

Dispute 2 — “GHK-Cu modulates >4,000 human genes” vs methodological critique that this is Connectivity Map pattern-matching, not direct measurement.

Position A (Pickart-derived): Pickart, Vasquez-Soltero & Margolina 2014 BioMed Res Int 151479 and Pickart & Margolina 2018 Int J Mol Sci 19:1987 (PMID 29986520) interpret GHK’s behaviour in the Broad Institute’s Connectivity Map dataset as evidence that GHK modulates “more than 4,000” human genes, with implications for tissue regeneration, anti-cancer activity, anti-anxiety, DNA repair and proteasome activation. 🔴 single-group / Skin Biology Inc affiliation ⚠️.
Position B (methodological critique — present in cosmetic-chemist commentary and implicit in the absence of independent replication): Connectivity Map produces signature-similarity scores between a query compound’s gene-expression pattern and reference patterns; matches do not equal direct demonstration that the query compound regulates those genes through a defined mechanism. The “4,000+ gene” claim is widely recycled in community write-ups (Niddam, Campbell, Aseir Auxano marketing) without engagement with this distinction. The 2025 Mao paper (Front Pharmacol; Jining Medical University) is the first major non-Pickart-lab mechanistic study and addresses a single pathway (SIRT1/STAT3) in a single mouse model — it does not address or replicate the 4,000-gene claim.
Resolution: No resolution in the published literature; the Pickart interpretation has not been formally retracted, and no formal rebuttal paper exists.

Dispute 3 (methodological, not substantive) — Topical permeation as a delivery-system problem.

Position A: Standard aqueous cosmetic SKUs deliver “almost no peptide or copper permeating through intact human skin” without specialised carriers [Peer-reviewed — Mortazavi 2025].
Position B (industry response): Lipid-nanocarrier (Badenhorst 2016), microneedle, ionic-liquid microemulsion (PMC10643103 2024) and other engineered delivery systems can achieve meaningful penetration.
This is not a substantive dispute about whether GHK-Cu works topically — it is a delivery-system constraint that both sides accept. It belongs in the Bottom-Line Note as a calibration on which SKUs are credible.

Other potential disputes that did NOT meet the v2 bar:

“Copper uglies” (anecdotal claim of accelerated visible aging from chronic high-dose copper-peptide use) — community/anecdotal, no published rebuttal needed.
5-α-reductase inhibition claim (Tressless 2024 community thread) — community claim, no peer-reviewed engagement; belongs in Section 7B.

No retraction signals identified on any cited primary reference as of 2026-05-13 (PubMed retraction-check across Pickart 1973; Pickart & Thaler 1973; Maquart 1988+; Hinek 1994; Pyo 2007; Lee 2016 PMID 27489425; Pickart 2014; Pickart & Margolina 2018 PMID 29986520; Bal 2021; Mao 2025 PMID 40672369; Mortazavi 2025).

7B. Community Evidence Layer

GHK-Cu sits across two largely separate optimization audiences that rarely cross-pollinate: the topical-cosmetic audience (skincare nerds, r/SkincareAddiction, r/AsianBeauty, beauty-science bloggers, “skin longevity” TikTok) and the injectable-peptide audience (r/Peptides, biohacker podcasts, Jay Campbell-adjacent influencers, hair-loss boards including Tressless). The two worlds use different vocabularies and cite different authorities.

Adoption timeline. ProCyte / Skin Biology / Neutrogena cosmetic era through the 1990s and early 2010s; Deciem NIOD CAIS (2014–2017) pulled GHK-Cu into Reddit skincare discourse; Lab Muffin Beauty Science’s December 2016 NIOD CAIS review is the cosmetic-chemist touchstone. The injectable grey-market phase ran roughly 2018–2022, driven by the Ben Greenfield podcast appearances with Jay Campbell and Nick Andrews (Aseir Custom / Auxano launch) and by jaycampbell.com peptide-protocol write-ups. Infusion Clinic ABQ reports “in 2020, the FDA severely restricted/eliminated the ability to obtain GHK-Cu injectable”; community sourcing shifted to research-chemical vendors. The current 2023–2026 phase is a TikTok skin-cycling / skin-longevity revival on the topical side, plus 503A compounding pharmacies (Salhab Pharmacy, Tampa) re-entering a quasi-clinical channel on the injectable side.

Documented protocols. The injectable side has converged on 1–2 mg/day sub-Q with 30-on / 30-off (Perfect B) or 8-on / 4-off intensive (SeekPeptides) cycling; 50 mg powder vials reconstituted in 2 mL bac water to 0.5 mg/mL; insulin syringe injection abdomen, before bed. The topical side has converged on 1–2% concentration (occasionally 5%) once or twice daily, layered away from vitamin C, retinoids and low-pH acids. Hair-stack protocols vary: 1 mg/day sub-Q + weekly microneedled topical + finasteride + ketoconazole is a documented Tressless example (Jun 4 2024). Both routes meet the ≥3-source threshold for “codified community practice.”

Most-cited claimed effects: wrinkle reduction / collagen stimulation (widespread); improved skin barrier / firmness / elasticity (widespread); scalp hair regrowth / follicle enlargement (common, Tressless logs); wound-healing acceleration / scar minimization (common); “systemic anti-aging via gene-expression resetting” / “youthful DNA peptide” (common — Niddam, Campbell, recycled Pickart); joint/tendon support (occasional — Greenfield/Aseir 2020); 5-α-reductase inhibition (contested — Tressless thread Jan 24 2024); COPD reversal / post-COVID lung recovery (occasional — HealthUnlocked); stem-cell activation, gut-barrier support, gray-hair reversal, anti-anxiety / DNA repair (single-source / fringe). The single-source claims uniformly trace back to the Pickart 2015/2018 papers recycled into community content without engagement with the underlying Connectivity Map argument.

Most-cited side effects: painful / stinging injection (common); skin irritation or reduced efficacy when layered with vitamin C / retinol / AHAs (common); copper-staining of clothing / pillowcases (occasional); “blue urine” / copper-overload anxiety (anxiety-only, not substantiated by any cited urinalysis); injection-site bruising; reconstitution-instability degradation. No serious adverse events are widely reported — the dominant community frame is “well-tolerated but watch copper status.”

Community dissent (the parts not to smooth over): topical-only purists vs injectable advocates; bioavailability skeptics on the sub-Q route (“is injectable GHK-Cu even doing anything systemically?”); Pickart as foundational reference vs Pickart as single-source dependency (Nathalie Niddam’s joke on The Energy Blueprint that the bioregulator community has not fully claimed GHK-Cu “because Khavinson didn’t discover it — Loren Pickart did”); copper-toxicity worriers vs “copper is chelated, not free”; the GHK-Cu / vitamin-C / retinoid formulation-stability split.

Stack patterns. GLOW stack — GHK-Cu + BPC-157 + TB-500 (Jay Campbell canonical write-up). Wolverine stack — BPC-157 + TB-500 with GHK-Cu added for skin/scar. Longevity stack — GHK-Cu + epitalon + thymosin α-1, sometimes adding sermorelin/ipamorelin (Niddam, Better Health Guy Ep 212; Dr. Stephanie Estima podcast July 15 2024). Hair stack — GHK-Cu + AHK-Cu + minoxidil ± finasteride ± microneedling ± RU58841. Topical layering — GHK-Cu + Matrixyl, + niacinamide, + hyaluronic acid; alternate-night discipline with retinoids/acids. GHK-Cu + C60 (Aseir Auxano). GHK-Cu + NAD+ + methylene blue (Young Goose Blue Peptide Spray; Niddam endorsement, code NAT10).

Vendor / supply. Cosmetic-grade: NIOD CAIS 1% and 5% (~~$90–$290 AUD; two-bottle activator system, 6-month post-mix shelf life); The Ordinary “Buffet + Copper Peptides 1%” (~~$30); Skin Biology Inc (Pickart’s own brand); Aseir Auxano Serum A + Serum B (GHK-Cu + C60); For Beloved One; Young Goose; Neurogan Health body lotion 5000 mg / 8 oz. Grey-market injectable: Limitless Life, Peptide Sciences, BioLongevity Labs, Pure Peptides, Swolverine. 503A compounding pharmacies (Salhab Pharmacy, Tampa) re-entered the channel as the “compliant” alternative — though as of 22 April 2026 they cannot legally compound under 503A (Section 4.1). Injectable powder vials ~$60–80; 50 mg powder $25–75; cosmetic serums $30–180.

QC issues. Recurring “is this real GHK-Cu or just GHK without the copper” question — distinguishable by the blue tint when properly complexed. Reconstitution stability is the dominant QC theme. Third-party mass-spec / HPLC reports from community-recognized labs (Janoshik, Jano Labs) for GHK-Cu vendors are notably thinner than for tirzepatide or BPC-157 — no high-profile public Janoshik COA for a major GHK-Cu vendor has surfaced at this review; vendor self-attested testing (Neurogan) is the dominant documented QC practice. This is itself a community-evidence gap and a useful broker signal.

Community Score breakdown: Usage volume 20/25 · Protocol codification 17/25 · Reported effect consistency 17/25 · Time in circulation 22/25 · Total 76/100.

8. Safety Profile

Topical adverse events: Mild erythema, transient pruritus, occasional allergic contact dermatitis. The “copper uglies” community claim — anecdotal accelerated visible aging from chronic high-dose copper-peptide use — is attributed by some authors to MMP-1 upregulation; no controlled human evidence beyond mechanistic plausibility.
Injectable adverse events: No systematic safety dataset in humans. Practitioner reports include transient injection-site reactions and rare nausea/dizziness, but these are not in indexed trial literature ⚠️. Community-reported injection pain (Kyal Van Der Leest on Ben Greenfield: “as a copper thing to inject it can actually be quite painful”) is consistent across sources.
Theoretical concerns with chronic injection:
- Systemic copper accumulation (Wilson’s disease contraindication; theoretical risk in any copper-handling impairment).
- Immunogenicity / impurity-related risks — explicitly cited by FDA as the basis for Category 2 placement in September 2023 [Regulatory — FDA 503A Safety Risks Summary 2023]. These concerns were not retracted by the April 2026 administrative removal, which was triggered by nomination withdrawal, not by FDA re-evaluation of the safety dossier. This is the single most under-discussed point in community write-ups, which treat the April 2026 removal as a regulatory softening rather than what it is: a procedural reset with the safety concerns still on file.
- Mitogenic / pro-angiogenic mechanism raises a non-quantified concern about subclinical neoplasia stimulation (no human evidence either way; the Pickart group has separately argued the opposite — an anti-cancer effect — in preclinical data 🔴).
Absolute contraindication: Wilson’s disease, for any systemic copper-delivering compound, on first principles.
Pregnancy / lactation: No data.
MedWatch signals: None public for GHK-Cu as of 2026-05-13.
Retraction status of cited literature: None identified on PubMed for any foundational citation as of 2026-05-13.
Single-research-group dependency: A very large fraction of the foundational mechanistic claims trace to Pickart and Skin Biology Inc 🔴. Mao 2025 (Jining Medical University) is the most prominent recent independent mechanistic confirmation, but in a colitis model, not human skin.

9. Drug and Cosmetic Interactions

Topical low-pH actives (high-concentration L-ascorbic acid, glycolic acid, salicylic acid): reduce stability of the Cu–peptide chelate; co-application in the same layer is empirically degradative.
Topical retinoids: no direct chemical incompatibility, but combined irritation potential.
Systemic copper-chelating drugs (penicillamine, trientine, ammonium tetrathiomolybdate): theoretical antagonism if GHK-Cu administered systemically; clinically relevant to Wilson’s disease management.
Zinc: theoretical competition at copper-transport (CTR1) and chelation sites; no quantified clinical interaction data, but raised consistently across cosmetic and injectable community discussions (Disclosed Labs, Neurogan FAQs).
Thiol-rich agents (high-dose oral or topical glutathione, N-acetylcysteine): may reduce Cu(II) to Cu(I) and alter peptide-metal coordination [Mechanistic — Bal 2021].

10. Research Gaps

Independent (non-Pickart, non-ProCyte, non-Skin-Biology-Inc) human RCTs in photoaging at adequate power — Mao 2025 is an early independent mechanistic study, but no comparable independent human RCT body exists 🔴.
Dose-finding for systemic / injectable indications — completely absent in the indexed human literature. The optimization-audience injectable use is unanchored to any human pharmacokinetic or pharmacodynamic dose-response dataset.
Head-to-head versus becaplermin (Regranex) in diabetic foot ulcers — never conducted; ProCyte’s own Phase III was placebo-controlled and failed.
Confirmatory Horvath / GrimAge / DunedinPACE epigenetic-clock human dataset — the “epigenetic age reversal” claim is currently supported only by Connectivity Map gene-signature pattern matching and a single industry press release ⚠️🔴.
Larger, blinded, vehicle-controlled hair-growth trials at a single characterised concentration, with ≥24 weeks of follow-up, standardised trichoscopic endpoints, and GHK-Cu isolated from confounding co-actives.
Chronic-injection safety pharmacology — copper accumulation, immunogenicity, oncogenic concern: basic toxicology not in the public peer-reviewed record at community-relevant doses.
Head-to-head delivery-system comparison — microneedle vs liposome vs ionic-liquid microemulsion vs simple aqueous, on a single endpoint, with skin-penetration quantification.
Mechanism verification for hair growth beyond Pyo 2007 / Lee 2016, ideally with stem-cell niche imaging.
Independent verification of secondary-aggregator-cited 2022–2025 trial readouts (Dermatologic Therapy 71-woman 1% trial; 2024 multicenter 0.05% post-laser study; Japanese 0.02% lotion 2025).
Community-side QC gap: publicly accessible Janoshik / Jano Labs COAs for major GHK-Cu vendors — present for tirzepatide and BPC-157, thin for GHK-Cu.
Anti-doping detection-method gap: no published WADA-laboratory LC-HRMS detection method for exogenous GHK-Cu. The free tripeptide is endogenous in plasma; an exogenous-administration test would require copper-stable-isotope tracing or a labelled synthetic analogue.

11. Bottom-Line Encyclopedia Note (≤150 words)

GHK-Cu carries an unusual evidence profile: a real but narrow 1996 FDA 510(k) Class I wound-dressing footprint (Iamin Gel, ProCyte, discontinued); a failed 1994 511-patient diabetic-ulcer Phase III pivotal; decades of small, mostly industry-funded topical cosmetic RCTs in photoaging with consistent but modest collagen/wrinkle endpoints; near-total absence of human pharmacokinetic, dose-finding or safety data for systemic injection; and a foundational mechanistic literature heavily dominated by one research group (Pickart / Skin Biology Inc) 🔴. As of 22 April 2026 FDA 503A update, GHK-Cu in any route — topical or injectable — is no longer in Category 1 or Category 2; both nominations were withdrawn, and PCAC consultation is scheduled before the end of February 2027. It is therefore not legally compoundable under 503A in the US in the interim. Not named on the WADA 2026 List; injectable use carries default S0 risk for tested athletes. The optimization-audience injectable use is unanchored to peer-reviewed human data.

11B. Gap Analysis

GHK-Cu occupies different cells of the four-cell gap matrix for different indications. This is the broker-stance section.

Indication	Community signal	Science signal	Cell	Subclassification
(a) Topical anti-aging cosmetic	High (widespread, 30-year lineage, mainstream cosmetic SKUs)	Moderate (B/45 — multiple positive RCTs but industry-funded, no Cochrane, topical permeation problem unresolved)	Convergent (high/moderate-high)	Aligned at low effect-size level. Community expectations on this indication track approximately with the science.
(b) Topical wound healing / post-procedure recovery	Moderate (Jay Campbell GLOW stack; post-microneedling cosmetic use)	Moderate (B/40 — historical 510(k) device clearance; positive small RCTs; negative pivotal Phase III; IWGDF 2024 does not recommend)	Mostly convergent	Cosmetic / post-procedure use plausible; drug-grade wound-healing claim does not hold.
(c) Hair growth (topical)	Moderate (Tressless logs; Greenfield Episode 499; AHK-Cu / minoxidil stacks)	Low–moderate (C/30 — Lee 2016 + small confounded combination trials; Pyo 2007 ex vivo; no Cochrane)	High community + Low–moderate science → tested-mixed	Modest, adjunctive vs minoxidil at best. The “potent 5-α-reductase inhibitor” claim (Tressless Jan 24 2024) is untested in dedicated trials and contested in community replies.
(d) Systemic / injectable anti-aging — the primary optimization-audience purchase	High (codified 1–2 mg/day sub-Q protocols across Perfect B, SeekPeptides, Jay Campbell, Disclosed Labs; named biohacker endorsements; sustained vendor channel through April 2026 503A reset)	Very low (D/5) — no human RCT in any systemic indication; no published human PK/PD; no safety pharmacology at chronic doses; not legally compoundable under 503A; default WADA S0 risk	High community + Low science → UNTESTED. This is the canonical “community ahead of science” cell.	The injectable indication has zero human trial data. The community-protocol convergence (1–2 mg/day sub-Q, 30-on / 30-off) is not derived from any human dose-finding study — it is a transposition of cosmetic-concentration logic into a research-chemical sub-Q vial. The “youthful DNA peptide” / “epigenetic age reversal” framing recycles the Pickart Connectivity Map pattern-matching argument, which is mechanistic plausibility, not human pharmacodynamics.
(e) Lung repair / COPD reversal / post-COVID lung	Occasional (HealthUnlocked thread, Infusion Clinic ABQ blog post)	Effectively zero (no peer-reviewed human evidence)	Low–moderate community + Low science → UNTESTED	The claim circulates because Pickart’s secondary review touched it and a single forum thread amplified it. No human trial exists.
(f) Anti-anxiety / DNA repair / proteasome activation	Single-source (Pickart-derived, recycled into Niddam / Campbell content)	Zero in humans	Single-source community + Zero science	Mechanistic-plausibility argument only; treat as preclinical-speculative for encyclopedia purposes.

Specific gap-named items where community claims outrun science:

Injectable systemic anti-aging at 1–2 mg/day sub-Q — no human RCT, no human PK, no human safety pharmacology. (UNTESTED.)
Epigenetic-clock reversal — Connectivity Map ≠ Horvath/GrimAge/DunedinPACE. (UNTESTED on the clock endpoint specifically.)
5-α-reductase inhibition (Tressless 2024) — no isolated trial; Kuceki 2025 was a triple-active combination. (UNTESTED in isolation.)
COPD / lung repair / post-COVID lung — Pickart secondary review claim; no human trial. (UNTESTED.)
Joint / tendon recovery (Greenfield 2020 friend anecdote, 2–3 mg sub-Q before run) — no human trial. (UNTESTED.)
Gut barrier / GI stem-cell support — Kyal Van Der Leest single-source oral formulation pitch + Mao 2025 mouse colitis. (UNTESTED in humans; preclinical signal in murine model.)
“Most evidence-based anti-aging peptide” framing — defensible only for the topical cosmetic indication, where Tier B sits. Generalizing the topical evidence to systemic indications is a category error widely committed in community communications.

Specific gap-named items where science exists but community ignores it:

The 1994 511-patient pivotal Phase III failure — visible in industry-trade press and central to ProCyte’s pivot from drug to device; effectively invisible in community communications.
FDA Category 2 safety basis (immunogenicity / impurity concerns, Sep 2023) — the basis for Cat 2 placement was not retracted; the April 2026 administrative removal was a nomination-withdrawal procedural event, not a safety re-evaluation. Community write-ups read the April 2026 update as regulatory softening; that’s the opposite of what happened.
Topical permeation as a delivery-system bottleneck — Mortazavi 2025 explicitly says standard aqueous cosmetic SKUs produce “almost no peptide or copper permeating through intact human skin.” The cosmetic-chemist tail of the community knows this; the mainstream skincare audience does not.
Single-research-group dependency 🔴 — the Niddam joke about Khavinson vs Pickart is the closest the community comes to engaging this issue; Reddit skeptics raise it occasionally but it does not durably modify the canonical Niddam / Campbell narrative.

12. Three Paths

Definition, not prescription. Each path describes a practice; none is endorsed.

Conservative path

Gates: (1) independent (non-Pickart, non-cosmetic-industry-funded) Phase 2 RCT in photoaging or wound healing with adequately powered effect-size confirmation; (2) Cochrane Systematic Review supporting at least one indication; (3) for any systemic use — peer-reviewed human Phase 2 dose-finding RCT with safety pharmacology; (4) FDA 503A Category 1 placement or full drug approval somewhere major.

Current state vs gates:

Gate 1 (independent confirmatory RCT): not met. Mao 2025 is mechanistic in a mouse model.
Gate 2 (Cochrane SR): not met. No SR exists. IWGDF 2024 actively does not recommend.
Gate 3 (human Phase 2 dose-finding for systemic): not met. Zero human systemic trials.
Gate 4 (regulatory approval / 503A Cat 1): not met. Both routes removed from the 503A bulks process April 2026; PCAC consultation pending Feb 2027; no NDA/IND on file.

Result: Conservative path supports only the topical cosmetic indication, using reputable cosmetic SKUs. All other uses — including all injectable / systemic uses — fail the conservative gate.

Moderate path

Treat the compound at its current Tier with monitoring. For topical: 1–2% INCI Copper Tripeptide-1 cosmetic serum or cream from a reputable brand (NIOD CAIS, The Ordinary Buffet + Copper Peptides 1%, Skin Biology Inc, Aseir Auxano two-part system, Neurogan body lotion). Apply once daily or split AM/PM. Layer alternate nights from retinoids, vitamin C and AHAs. Expect modest collagen / wrinkle endpoints over 8–12 weeks at the effect-size range reported in industry-funded trials (Leyden 2002, Badenhorst 2016). Do not lean on the “youthful DNA peptide” / epigenetic-clock framing — it is not what the human trial evidence supports.

Baseline panel (cosmetic use): not required for topical at INCI-permitted concentrations.

Monitoring (cosmetic use): none; routine dermatologic self-monitoring sufficient.

Cost: ~$30 (The Ordinary) to ~$290 AUD (NIOD CAIS 5%).

The moderate path does not extend to systemic / injectable use under current evidence. There is no peer-reviewed human PK/PD or safety pharmacology to anchor a moderate-path injectable monitoring plan.

High-tolerance path

Acknowledges no gates met for systemic use. Describes the community mitigation stack as it is actually practiced, with explicit broker caveats:

Regulatory caveat: Not legally compoundable under 503A in any route in the US as of 22 April 2026. Acquisition channel either (a) 503A compounding pharmacy with prescription (legally complicated post-April-2026), or (b) grey-market research-chemical vendor.
Anti-doping caveat: Default WADA S0 for tested athletes; no TUE possible (S0 substances have no approved therapeutic indication). Topical cosmetic use is exempt from this consideration.
Community-standard protocol: 1 mg/day sub-Q for days 1–15, escalate to 2 mg/day days 16–30, 30-on / 30-off cycle, abdomen, insulin syringe, evening dose, reconstituted 50 mg vial in 2 mL bacteriostatic water → 0.5 mg/mL. Note: this protocol is not derived from human dose-finding; it is a community convergence with no clinical anchor.
Bloodwork (community practice — not validated): baseline + 30/60 day check including serum copper, ceruloplasmin, zinc:copper ratio; Wilson’s-disease screen (24h urinary copper, ceruloplasmin, ALT/AST baseline) before initiation; CBC and CMP standard.
QC mitigation: insist on a vendor-provided third-party COA (Janoshik / Jano Labs); be aware that public COAs for GHK-Cu are thinner than for tirzepatide and BPC-157 — treat that gap as itself a quality signal. Verify blue tint on reconstitution as a crude indicator that copper is present and chelated; do not trust uncolored reconstituted solutions.
Storage: 28-day fridge limit post-reconstitution; protect from light.
Dose ceiling: community top doses (Greenfield friend “2–3 mg sub-Q before run, 1 mg after”) have no safety anchor; cap below community top-dose practice.
Physician dialogue: explicit pre-cycle conversation with a physician about Wilson’s-disease screening, copper status, and the immunogenicity concerns FDA cited as the 2023 Category 2 basis (which were not retracted by the April 2026 nomination-withdrawal procedural event).

The high-tolerance path is documentation of community practice, not a recommendation. Anyone considering it should weigh: zero human RCT evidence for the indication, default WADA S0 risk, no legally compliant US compounding channel, and the unresolved FDA immunogenicity concerns.

13. Key References

Scientific:

Foundational mechanism (single-group dependency 🔴):

Pickart L, Thaler MM. 1973. Nature New Biol 243:85–87 — original plasma isolation.
Pickart L, Margolina A. 2018. Int J Mol Sci 19:1987; PMID 29986520 — “Regenerative and Protective Actions” review ⚠️ Skin Biology Inc affiliation 🔴.
Pickart L, Vasquez-Soltero JM, Margolina A. 2014. BioMed Res Int 151479 — Connectivity Map interpretation 🔴.
Pickart L, Margolina A. 2015. BioMed Res Int; PMID 26236730 — cosmetic review 🔴.

Mechanism (independent of Pickart):

Maquart FX series 1988–1993; Simeon, Wegrowski, Bontemps, Maquart. 2000. J Invest Dermatol 115:962 — collagen synthesis.
Hinek A et al. 1994. Mech Ageing Dev 77:211 — aged-rat wound healing.
Pyo HK et al. 2007. Biofactors — dermal-papilla protection.
Bal W et al. 2021. Inorg Chem; PMC8653159 — Cu(II)/Cu(I) transfer kinetics.
Mao S, Huang J et al. 2025. Front Pharmacol 16:1551843; PMID 40672369; PMC12263609 — DSS-colitis SIRT1/STAT3 axis. First major non-Pickart-lab mechanistic study.
Mortazavi S, Vadoud S, Moghimi H. 2025. Bioimpacts 15:30071 — topical permeation review.
Medsci tripeptide wound-healing review 2024; PMC12595317.

Human clinical trials (mostly industry-funded ⚠️):

Mulder GD et al. 1994. Wound Repair Regen 2:259; PMID 17147644 — n≈30 diabetic ulcer RCT.
ProCyte unpublished 1994 Phase III, n=511 — negative pivotal [Industry-trade contemporaneous].
Abdulghani et al. 1998. Disease Manag Clin Outcomes 1:136–141.
Leyden J et al. 2002 AAD abstract — periorbital photoaging.
Finkley MB, Appa Y, Bhandarkar S. 2005. Cosmeceuticals and Active Cosmetics, Marcel Dekker, 549–563 ⚠️ Neutrogena.
Miller TR et al. 2006 — post-laser-resurfacing split-face.
Lee WJ et al. 2016. Ann Dermatol; PMID 27489425 — GHK + 5-ALA scalp RCT.
Badenhorst T et al. 2016. J Aging Sci 4:166 — lipid-nanocarrier vs Matrixyl 3000 vs vehicle.

Regulatory:

FDA, “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A,” updated 22 April 2026 — fda.gov/media/94155.
FDA 510(k) clearance, Iamin Hydrogel, ProCyte, 7 February 1996.
FDA 510(k) K964468 — Iamin Wet Dressing (Copper-Saline).
FDA Class 2 Device Recall record id 135054.
FDA 503A Safety Risks Summary, September 2023.
WADA 2026 Prohibited List and Monitoring Program, in force 1 January 2026.
IWGDF 2024 guideline on diabetic foot.

Trial registry:

NCT05239615 — photoaging Phase II, completed 2024, no results posted.
NCT04892136 — hair growth, terminated 2023.
NCT02898454 — androgenetic alopecia, completed 2019.

Press release / non-peer-reviewed (flagged):

Yuvan Research Inc, EurekAlert / Practical Dermatology, May 2023 — NEEL Gel ⚠️.
ProCyte / Seattle Times / Pink Sheet / Scrip / BioWorld / UPI 1992–1997 — Iamin Phase III failure and 510(k) device clearance [industry-trade].

Academic secondary:

PubChem CID 73587187 (complex); CID 92805 (free GHK); DrugBank DB12815.

Community:

Protocol documents:

Perfect B clinic — “GHK-Cu Dosage and Protocol: A Medical Provider’s Guide to the 30-Day Cycle.”
SeekPeptides — “GHK-CU Peptide Dosage: Complete Guide.”
Jay Campbell — “GHK-Cu Dosage for Hair Growth and Skin Rejuvenation”; “GLOW Peptide Protocol: BPC-157, TB-500 & GHK-Cu”; “How (And Why) Copper Peptide GHK-Cu Gives You Healthier, Younger Skin”; “Quantum Peptides.”
Disclosed Labs — “GHK-Cu Reconstitution Calculator.”

Named figure podcast / Substack content:

Ben Greenfield with Jay Campbell + Nick Andrews — “The 2 Most Potent Hair Growth & Hair Loss Reversal Molecules: C60 & GHK-Cu” (2020).
Ben Greenfield, Episode 499 (2024) — “Hair Growth Peptides, Smart Drugs & Aging Anxiety.”
Ben Greenfield with Kyal Van Der Leest — “The Coolest, Craziest Peptides & Where To Get Them” (2024).
Nathalie Niddam on Ari Whitten’s The Energy Blueprint; Better Health Guy Episode 212; Dr. Stephanie Estima’s BETTER! podcast (Jul 15 2024) timestamp 52:53 “GHK-CU: The Youthful DNA Peptide”; Young Goose Blue Peptide Spray endorsement.

Cosmetic-chemist sources:

Lab Muffin Beauty Science — NIOD CAIS review (Dec 10 2016); For Beloved One series review; snail-slime / peptide formulation pieces.
Westlake Dermatology — “A Dermatologist’s Take on the Copper Peptide (GHK-Cu) Trend.”
Salhab Pharmacy — “GHK Cu Peptide FDA Clinical & Legal Status 2026.”

Reddit / forum:

r/tressless — multiple threads 2024 (Jun 4, Sep 1, Jan 24, Nov 25).
r/Peptides — recurring injection-pain and copper-overload threads (no specific thread isolated at this review; flagged as gap).
HealthUnlocked British Lung Foundation — “GHK-CU reverses emphysema???” thread.
Tressless wiki — “What is GHK-Cu and why is it said to be a ‘miracle’ for hair?”

Vendors:

NIOD / Deciem CAIS 1% and 5%; The Ordinary; Skin Biology Inc; Aseir Auxano Serum A + B; For Beloved One; Young Goose; Neurogan Health.
Grey-market: Limitless Life, Peptide Sciences, BioLongevity Labs, Pure Peptides, Swolverine.

14. Audit / Refresh Trail

Composed: 2026-05-14.
Next refresh triggers:
- 23 July 2026 FDA PCAC meeting (July subset — BPC-157, KPV, MOTs-C, TB-500, Emideltide/DSIP, Epitalon, Semax). GHK-Cu not in this subset but the meeting may set procedural precedent for the February 2027 subset.
- Before end of February 2027 — FDA PCAC consultation on GHK-Cu (both routes). Any movement onto Category 1 or onto the 503A bulks list would be a material change.
- WADA 2027 Prohibited List preview (typically late September / early October 2026) — check for named addition of GHK-Cu under S0 or S2.
- CuHeal trial NCT confirmation and any Phase 2 results posting for NCT05239615.
- Independent peer-reviewed RCT in photoaging from a non-Pickart, non-cosmetic-industry group.
- Retraction of any Pickart / Skin Biology Inc foundational citation — none as of 2026-05-13.
- Vendor-landscape shifts: any high-profile Janoshik / Jano Labs COA publication for a major GHK-Cu vendor; any FDA enforcement action against a research-chemical channel; any 503B outsourcing-facility movement.
- Direct Reddit thread pull for r/Peptides and r/SkincareAddiction GHK-Cu-specific threads (gap to close at next refresh).

15. Comparative-Table Note (v2)

Comparative table affected: Tissue repair / wound class.

Other compounds in this class: BPC-157, TB-500 / Tβ4, Pentadeca Arginate (PDA), AHK-Cu, Matrixyl, cibinetide / Ara-290.

Action: GHK-Cu is the first entry in the tissue-repair class. Create the comparative tissue-repair table once a second compound in this class is composed. The natural candidates for the second composition in this class, given community traffic and 2026 regulatory salience, are BPC-157 (highest community volume in the class; 23 July 2026 PCAC meeting will be a forcing function) or TB-500 / Tβ4 (frequently stacked with BPC-157 and GHK-Cu in the GLOW / Wolverine protocols).

Fields the GHK-Cu row will affect when the comparative table is created:

WADA status column (not listed; default S0)
FDA approval column (legacy 510(k) device clearance; no drug; 503A withdrawn April 2026)
Primary indication column (topical anti-aging cosmetic; secondary topical wound; tertiary hair)
Evidence tier column (B/45 primary; D/5 for systemic injectable)
Dose range column (topical 0.1–4%; injectable community 1–2 mg/day sub-Q with no clinical anchor)
Half-life column (not characterised in humans for injectable; topical PK dominated by stratum-corneum permeation)
Single-group dependency column (🔴 yes — Pickart / Skin Biology Inc)
Independent replication column (mechanism: yes since Mao 2025; clinical: weak)
Negative-pivotal column (yes — ProCyte 1994 511-patient Phase III in diabetic foot ulcer)